The MOR Code - 2026 May
The MOR Code
Architecture, neuroscience, and the receptor system underneath every space you walk into.
One letter a month. The science I'm actually using to design offices, campuses, and community spaces around the human nervous system. Free. No spam. Unsubscribe in one click.
A short note to open the dress rehearsal — and a frame for everything that follows.
Welcome. I'm Michelle Opal Rutkowski, a licensed architect and the author of a forthcoming book — MOR: The Design of Our Addictions. I run MOR Studio, where we design spaces around how the human nervous system actually works. The reason I write this letter is bigger than the studio.
A note on this issue. What you are reading is the dress rehearsal — Draft No. 00. The architecture and the science are real; the format is still being sharpened. Issue 01 ships in June, in the form this draft is teaching us to build. I would rather you see the seams than wait for them to be hidden.
A few years ago, a piece of science changed my life. It is the science of a single receptor in the body that has been called the addiction receptor for forty years and turns out to be woven through almost every system involved in thriving — mood, sleep, immunity, the gut, the way we recover, the way we feel like ourselves on a good day. It is also exquisitely sensitive to the inputs most of us have never been told to track: light, movement, stillness, what the room looks like, how the day is shaped.
The MOR Code is the monthly dispatch where I bring that science inside, in plain English. It is for the people designing the spaces and the people living inside them. For anyone who has felt the difference a room can make and not had a name for what was happening in their body.
This month, the headline is simple. Architecture is being measured by the body. Several studies this spring put real instruments onto people inside real buildings — fNIRS, an optical sensor that reads blood-oxygen flow at the surface of the brain · HRV, the millisecond variation between heartbeats that tracks how relaxed or activated the nervous system is · EEG, scalp electrodes reading brainwave bands. Three windows into the body, opened at the same time, in the same room. I cannot wait for you to read what came back.
Michelle Opal Rutkowski, AIA
Architect · MOR Studio / Creator · My Dopamine Blueprint™
New to the reward system? Start with the four inputs.
The mu-opioid receptor is the body's reward switch.
Known in the literature as MOR, it sits across the brain, immune system, gut, and skin. It is the docking site for the body's own opioid molecules — endorphins, the ones that produce runner's high, the warm settle of a long conversation, the felt sense that this moment is enough. Well-fed by Connection, Discovery, Movement, and Rest, the receptor does what it was built to do: give you the felt sense of life worth showing up for.
A mu-opioid receptor antagonist — a quiet, reversible blocker of the same receptor this letter is about.
An antagonist is a molecule that occupies a receptor without activating it — it sits in the parking spot and keeps anything else from parking there. Naltrexone occupies MOR for a few hours and stops the body's own opioids from binding during that window. That single mechanism is why one 42-year-old, off-patent molecule keeps surfacing in autoimmune disease, long COVID, fatigue, dermatology, fertility, and now major depression — not as a niche addiction drug, but as a tool that recalibrates the reward system itself. Low doses (LDN, 1–4.5 mg) appear to do this through brief blockade: once the dose clears, the receptor system rebounds with more capacity and stronger endogenous tone than it had before. The MOR Code tracks the new science each month.
Each tile is a study, tagged by the input it acts on.
Each tile carries a small CDMR emblem in its lead pillar, and the pillar names sit color-coded above the headline. Two or three names means the finding fires more than one pillar at once. Each tile ends with a question the research opens up. Save the ones that move you.
One letter. Twelve to twenty studies. Read in fifteen minutes, useful for thirty days.
The Field Report
Six to eight new studies on architecture and the nervous system — with the reward-system mechanism that explains why the room moves the body folded in alongside them. Tagged by the input they act on: Connection, Discovery, Movement, Rest. Read by an architect, for the people deciding what gets built.
02What Naltrexone Did
A 42-year-old, off-patent molecule with a receptor that lives in tissues throughout the body. New studies plus integrated older literature, synthesized across the medical specialties that don't talk to each other — immunology, oncology, dermatology, gastroenterology, psychiatry, pain medicine, developmental biology, neuroplasticity. Tracked across the receptor's full footprint.
03The Library
Six to nine more papers worth knowing this month — fresh studies plus the occasional throwback when an older finding speaks to what's new. Tagged by pillar.
this month
The instruments caught up. Architecture now reads on fNIRS, HRV, and EEG — brain, heart, attention, all at once. The building is no longer a backdrop. It is a dose.
Designing The Spaces We Lead
Seven findings from the past 30–60 days, read through the lens of the people who specify, lead, and inhabit space — offices, campuses, learning environments, community rooms, and the home you sleep in tonight. The final tile is the reward-system mechanism running underneath every finding above it. Read in any order. The pillar bar at the top of each tile shows the reward-system filter at work.
The first study to read architecture from brain to heart — in the same subject, at the same time.
Nine façade configurations. Twenty subjects. Two instruments running at once. fNIRS reading blood-oxygen flow at the back of the brain. HRV reading the millisecond-level variation between heartbeats. Different façades pulled different brain–body responses; the data is reproducible. We are out of the territory where neuroarchitecture is a hypothesis. The instruments are listening.
Eight to nine minutes of nature reorganized the brain. Wetlands worked fastest.
EEG mapping across three urban green-space types: park, remnant forest, wetland. Within nine minutes, alpha was up and beta/gamma were down across all three. Wetlands delivered the most rapid stress recovery; manicured urban park was meaningfully behind. Nature works on the brain like a tuning fork — but only some natures hum at the right frequency.
The wall held the body in rest mode while the mind worked.
Living-wall exposure during cognitively demanding tasks significantly raised parasympathetic tone — measured as HF-HRV, the high-frequency band of heart rate variability that tracks the rest-and-restore branch. The shift happened during the mental effort, not after. The wall is no longer ornament; it is nervous-system infrastructure.
A walkable neighborhood causally produced more walking. Twins proved it.
A twin study tracking 7,400 individuals over eleven years found that for every 1% increase in neighborhood walkability, residents walked 0.42% more. A 55% walkability increase translated to nineteen extra minutes of walking per week — controlled for genetics, controlled for selection. The street grid, not the mood, was making the move.
Architecture is now in the brain-growth literature.
The hippocampus — the seahorse-shaped structure deep in the temporal lobe that runs memory and spatial navigation — keeps growing neurons throughout life. A new review formally entered architecture into that conversation, alongside exercise and novel environments, as a continuous input to adult neuron growth. Spatial complexity, daylight, and walkable variety are now inputs the field is naming.
Shaded vegetated areas were 12.7°C cooler in summer and 1.3°C warmer in winter.
The thermal envelope of a shaded outdoor space is its own microclimate. In peak summer the difference was 12.7°C; in winter, the same canopy held 1.3°C of warmth. Cognition, parasympathetic tone, and willingness to be outside at all track that envelope. Shade is not a luxury detail. It is the difference between a person walking and a person staying inside.
The mechanism underneath every finding above: dopamine teaches navigation, not just reward.
Recordings across the striatum during a navigation task found dopamine encoding trajectory errors — the gap between where the animal expected to be and where it actually was — as a signal separate from how good the reward itself was. The brain's mismatch signal is not one channel; it is running a parallel spatial prediction error in the same currency. Wayfinding, walkable variety, and legible neighborhoods feed a dopamine channel of their own. The map is not a metaphor. It is a learning signal.
“The building is no longer a backdrop. It is a dose.”— The MOR Code · Draft No. 00 · May 2026
What Naltrexone Did
A 42-year-old molecule, off-patent and sub-dollar-a-day, working across medical specialties that don't talk to each other. This section synthesizes new and integrated naltrexone research — what it did, what the trial design tells us, and what the mechanism keeps suggesting. New work leads; the integrated older literature fills in the picture where it makes the science more legible.
Naltrexone is the molecule that rewired my reward system from scratch. I took the full-dose pill through the Sinclair Method — naltrexone an hour before drinking, so the mu-opioid receptor was occupied during the exact moments alcohol would normally reward the brain. The reward loop quietly extinguished itself over months. I walked out the other side with a working reward system and a question that hasn't left: what else is this molecule doing that no one is naming? Ever since, I have been uncovering the language of reward and how it speaks to our biology at the receptor.
LDN is the same molecule at a low dose. Same mechanism: it occupies the mu-opioid receptor briefly, then clears — and the receptor upregulates over time. Brief occupancy. Lasting recalibration.
This is a 42-year-old, off-patent molecule with no industry sponsor — and a mu-opioid receptor system that lives in tissues throughout the body. That means LDN research is unfolding across medical specialties that don't talk to each other: immunology, oncology, dermatology, gastroenterology, psychiatry, pain medicine, developmental biology, neuroplasticity. This section exists to synthesize it across the silos. New work leads; integrated older literature fills in the picture where it makes the science more legible. Expect this body of work to multiply across the next decade as the specialties catch up to the receptor.
A portion of every dollar My Dopamine Blueprint™ earns funds independent research on this generic molecule — the work the industry has no incentive to do.
42 years old · Off-patent · Sub-dollar-a-day · Just getting started
Naltrexone quieted neuroinflammation — and the anxiety and depression that came with it.
In alcohol-exposed mice, naltrexone reduced microglial activation — the brain's resident immune cells shifting out of their inflammatory state and back toward a calm, surveilling one. The behavioral data tracked: anxiety and depression-like behaviors dropped alongside the inflammation. The signal underneath: naltrexone's reach extends well past receptor blockade into glial regulation. The same molecule, a wider hand.
The first registered LDN-for-depression trial reported null. The trial design is the story.
A randomized, double-blind, placebo-controlled trial of LDN added on top of existing antidepressant treatment in moderate major depressive disorder. n = 37. 12 weeks. Up to 4.5 mg/day. MADRS dropped 10.5 on LDN, 9.8 on placebo, p = 0.97. Flat. No movement on hsCRP. No movement on secondary measures. Reported honestly, the headline is: adjunctive LDN did not alter depressive symptoms in moderate MDD.
Read for mechanism, the trial design is its own finding. The window may be inside the rebound, not past it — receptor upregulation after transient blockade tends to register on a 60-day-plus curve; a 12-week endpoint catches the perturbation without giving the rebound time to express. The population was wrong for the hypothesis — moderate MDD on a working antidepressant is not the neuroinflammatory, anhedonic, reward-deficit substrate LDN theory predicts will respond. The authors themselves say so. The biomarker was peripheral, not central — hsCRP indexes systemic inflammation; the proposed mechanism is microglial. And there was no lifestyle arm. A capacity drug tested in lives that may produce no new ligands has nothing to bind to.
The pill creates the capacity. The life provides the ligands. This study tested the pill.
LDN for Long COVID: the most consistent off-label signal in the literature.
An Irish case series and a 2025 meta-analysis continue to show LDN improving fatigue, brain fog, and post-exertional malaise in long COVID — the same fingerprint the NIH RECOVER program is now testing in a pivotal trial. Brief receptor blockade. Endogenous opioid rebound. Glial calming. Three mechanisms, one molecule — and the cleanest off-label signal in the literature is still landing in a population (long COVID) that maps closely to the neuroinflammatory, reward-deficit substrate LDN theory predicts will respond. The null depression trial above tested a different population, on a shorter clock, with no lifestyle arm. Same molecule, different test.
- FibromyalgiaLDN re-analysis in fibromyalgia — Korean Journal of Pain reports sustained symptom reduction at three- and six-month follow-up, with the cleanest responder profile yet published.
- MCASLDN clinical update for Mast Cell Activation Syndrome — a new clinical writeup of LDN as a mast-cell stabilizer through TLR4 modulation, adding to the autoimmune-adjacent indication list.
- OncologyLDN in oncology — 2024 Cancers review on opioid growth factor / OGFr signaling and the tumor immune microenvironment — the receptor mechanism the depression trial did not measure.
The Library
Every other paper worth knowing this month, on the table, tagged by pillar. Nine tiles — seven new, two carried forward from April because they keep doing work.
Blue spaces deliver the fastest stress recovery on EEG.
A clean synthesis of the wetland-and-water literature: water-adjacent environments shift the brain into alpha-dominant rest faster than any other measured nature category. The takeaway is operational — water is not interchangeable with green.
A new neuroarchitectural framework, designed to be tested.
A formal scaffold linking design features to measurable nervous-system outputs — the kind of bridge the field has been missing. Built for replication, not rhetoric.
Hospital biophilic design works through four named mechanisms.
Stress reduction, attention restoration, positive distraction, and place-belonging — four converging pathways the new framework lays out and ties to outcomes. The hospital is now a named test case.
Wellness architecture trends 2026: neuroarchitecture is the paradigm shift.
An industry-side reading: the trade has officially named neuroarchitecture as the through-line of the next decade, not biophilia. The language is starting to match the science.
Circadian lighting reduced falls in elder care by 44%.
A tuned-spectrum lighting deployment in long-term care produced a measurable, large-effect drop in fall events. The body's clock is one of the few systems the building can talk to directly — the data is now operational.
Higher daylight exposure tracked with better cognitive performance.
A population-scale analysis tying time-in-daylight to cognition controls. Aperture, orientation, and time-of-day exposure are reading as cognitive design variables, not aesthetic ones.
Hospital sleep-wake rhythms are now an architectural input.
A wearable-driven study showing that hospital lighting, acoustic environment, and nursing-shift cadence collectively shape patient circadian recovery. The room is the second drug.
Walkability still reads as the cleanest public-health intervention in built form.
April's meta-analysis carries forward this month because the Duncan twin study in the Field Report is its causal mirror. Read together, the population data and the twin data say the same thing twice.
Long-term sunlight exposure at home tracked with better cognitive scores.
Carried forward because the Manchester daylight study and this longitudinal residential one converge: the home you live in is metering your exposure to the most reliable circadian signal we have. Aperture is a long game.
Read the previous issues.
The pilot dispatch
The private prototype that became this letter. Walkability, neurogenesis, and the first sketches of what would become the four-pillar framework.
Read →Coming next month
The next dispatch arrives mid-June, with the first audio reading of The MOR Code.
Subscribe to receive itGet the next one in your inbox.
One letter a month, the morning of the second Thursday. Architecture, neuroscience, and naltrexone news — written for the people deciding what gets built.
Your reward system is not something to fight. It is something to design around.
If one person came to mind while you were reading this, that's who this is for. Forward it to them.